Dynavax Technologies Corporation

09/22/2021 | Press release | Distributed by Public on 09/22/2021 05:13

COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial